Open AccessEfficacy of ixazomib for the treatment of relapsed/refractory multiple myeloma
Author(s) -
Zhi Li,
Shuying Guo,
Wanli Wang
Publication year - 2020
Publication title -
medicine
Language(s) - English
Resource type - Journals
SCImago Journal Rank - 0.59
H-Index - 148
eISSN - 1536-5964
pISSN - 0025-7974
DOI - 10.1097/md.0000000000020211
Subject(s) - medicine , ixazomib , multiple myeloma , refractory (planetary science) , oncology , intensive care medicine , lenalidomide , carfilzomib , physics , astrobiology
Background: Over the past years, ixazomib has been increasingly explored for the treatment of relapsed/refractory multiple myeloma (RRMM). However, its results are still contradictory. This study will explore the efficacy and safety of ixazomib for patients with RRMM. Methods: A systematic records search of Cochrane Library, PUBMED, EMBASE, CINAHL, ACMD, PsycINFO, WANGFANG, and China National Knowledge Infrastructure will be carried out from their origin to March 31, 2020 with no limitations of language and publication status. Trials will be selected by titles/abstracts, and full manuscripts by 2 independent authors. Data collection will be carried out from eligible trials based on the previous designed criteria. Study quality will be checked using Cochrane risk of bias, and statistical analysis will be administered by RevMan 5.3 software. Results: This study will summarize the current high-quality trials investigating the efficacy and safety of ixazomib for the treatment of patients with RRMM. Conclusion: The results of this study may provide convinced evidence on the evidence-based medicine level, and guidance for clinical practice and future studies. INPLASY Registration Number: INPLASY202040027.